semaglutide and thyroid disease (Ozempic) carries FDA warnings for C-cell tumors based on rodent studies, with emerging human data showing higher thyroid cancer risk in early users. Over 2,900 lawsuits allege inadequate warnings for Semaglutide and Tirzepatide: How do
Description
Key Takeaways GLP-1 therapy can lead to average weight loss of 518% according to clinical trials
The question is not whether these medications work
They are prepared by licensed pharmacies under federal and state compounding rules, based on individual prescriptions written by licensed clinicians
Potency decreases over time even under optimal storage
Eli Lillys patents on those two brand-name drugs are valid in the United States until 2036, but they are expiring in other countries
:max_bytes(150000):strip_icc()/thyroid-disease-and-diabetes-3289616_FINAL-fc8f13691b50435dba27b9cbf5528e57.png)
